Related Experiment Video
Updated: Apr 6, 2026

Assessing Cardiomyocyte Subtypes Following Transcription Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts
Published on: March 22, 2017
Reprogramming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?
Antje D Ebert1, Sebastian Diecke2, Ian Y Chen1
1Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA Institute of Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Scientists are using reprogramming and transdifferentiation to create patient-specific heart cells (cardiomyocytes) for disease research and potential therapies. This advance promises better understanding and treatment of heart disease.
Area of Science:
- Cardiovascular Biology
- Stem Cell Science
- Regenerative Medicine
Background:
- Heart disease is a leading cause of death and a significant global health issue.
- Stem cell advancements enable the generation of cardiomyocytes for research and therapy.
- Reprogramming and transdifferentiation are key biological processes in this field.
Purpose of the Study:
- To review methods for generating induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and induced cardiomyocytes (iCMs).
- To discuss the application of patient-specific cardiomyocytes in disease modeling and therapies.
- To highlight the potential of human disease-specific cardiomyocytes for advancing cardiovascular research.
Main Methods:
- Utilizing reprogramming to convert somatic cells into induced pluripotent stem cells.
- Employing transdifferentiation to directly convert one cell type into another.
- Generating induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and induced cardiomyocytes (iCMs).
Main Results:
- Reprogramming and transdifferentiation offer viable pathways to produce large quantities of cardiomyocytes.
- Patient-specific iPSC-CMs and iCMs are valuable tools for in vitro disease modeling.
- These cells hold promise for in vivo therapeutic applications in cardiovascular diseases.
Conclusions:
- Further refinement of human disease-specific cardiomyocytes will enhance understanding of cardiovascular disease mechanisms.
- Accelerated development of novel therapeutic options for heart disease is anticipated.
- Patient-specific cardiomyocytes represent a significant advancement in cardiovascular medicine.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
10:05Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
Related Concept Videos
Forced Transdifferentiation
Artificial...
Somatic to iPS Cell Reprogramming
iPS Cell Differentiation
Methods of Nuclear Reprogramming